Related references
Note: Only part of the references are listed.A phase I dose finding and biomarker study of TKI258 (dovitinib lactate) in patients with advanced melanoma
K. B. Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07)
R. von Moos et al.
ANNALS OF ONCOLOGY (2012)
Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation
Fei Su et al.
CANCER RESEARCH (2012)
Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition
W. Deng et al.
PIGMENT CELL & MELANOMA RESEARCH (2012)
Ipilimumab: A Novel Treatment for Metastatic Melanoma
Morgan E. Culver et al.
ANNALS OF PHARMACOTHERAPY (2011)
Analysis of GNAQ mutations, proliferation and MAPK pathway activation in uveal melanomas
Helena Populo et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2011)
Vertical Inhibition of the mTORC1/mTORC2/PI3K Pathway Shows Synergistic Effects against Melanoma In Vitro and In Vivo
Johannes Werzowa et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
mTOR pathway activation in cutaneous melanoma is associated with poorer prognosis characteristics
H. Populo et al.
PIGMENT CELL & MELANOMA RESEARCH (2011)
Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
Mohammad Atefi et al.
PLOS ONE (2011)
Genotype-Dependent Sensitivity of Uveal Melanoma Cell Lines to Inhibition of B-Raf, MEK, and Akt Kinases: Rationale for Personalized Therapy
Nicholas Mitsiades et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2011)
Vertical Targeting of the Phosphatidylinositol-3 Kinase Pathway as a Strategy for Treating Melanoma
Saadia A. Aziz et al.
CLINICAL CANCER RESEARCH (2010)
Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibition Results in Biphasic Alteration of Epidermal Homeostasis with Keratinocytic Apoptosis and Pigmentation Disorders
Karin Schad et al.
CLINICAL CANCER RESEARCH (2010)
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers
Patricia M. LoRusso et al.
CLINICAL CANCER RESEARCH (2010)
A phase 2 study of vatalanib in metastatic melanoma patients
Natalie Cook et al.
EUROPEAN JOURNAL OF CANCER (2010)
Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212
J. R. Infante et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma
Helena Populoa et al.
MELANOMA RESEARCH (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Mutations in GNA11 in Uveal Melanoma.
Catherine D. Van Raamsdonk et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The PI3K/Akt and mTOR/P70S6K Signaling Pathways in Human Uveal Melanoma Cells: Interaction with B-Raf/ERK
Narjes Babchia et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2010)
Suppression of mTOR complex 2-dependent AKT phosphorylation in melanoma cells by combined treatment with rapamycin and LY294002
J. Werzowa et al.
BRITISH JOURNAL OF DERMATOLOGY (2009)
Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma
Axel Hauschild et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Final Version of 2009 AJCC Melanoma Staging and Classification
Charles M. Balch et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates
Scott E. Woodman et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
Catherine D. Van Raamsdonk et al.
NATURE (2009)
A novel AKT3 mutation in melanoma tumours and cell lines
M. A. Davies et al.
BRITISH JOURNAL OF CANCER (2008)
Phase II trial of imatinib mesylate in patients with metastatic melanoma
K. B. Kim et al.
BRITISH JOURNAL OF CANCER (2008)
Akt and mutant V600EB-Raf cooperate to promote early melanoma development
Mitchefl Cheung et al.
CANCER RESEARCH (2008)
Targeted therapy for uveal melanoma
Pierre L. Triozzi et al.
CANCER TREATMENT REVIEWS (2008)
Axitinib (AG-013736) in patients with metastatic melanoma: A phase II study
J. P. Fruehauf et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers
Alex A. Adjei et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma:: final results of EORTC 18991, a randomised phase III trial
Alexander M. M. Eggermont et al.
LANCET (2008)
BRAFE600 in benign and malignant human tumours
C. Michaloglou et al.
ONCOGENE (2008)
Reduced expression of p16 and p27 is correlated with tumour progression in cutaneous melanoma
Amira Sanki et al.
PATHOLOGY (2007)
Overcoming apoptosis deficiency of melanoma - Hope for new therapeutic approaches
Juergen Eberle et al.
DRUG RESISTANCE UPDATES (2007)
The Rb family connects with the Tp53 family in skin carcinogenesis
Maria Fernanda Lara et al.
MOLECULAR CARCINOGENESIS (2007)
ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence
Linan Ha et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Low prevalence of RAS-RAF-activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions
James O. Indsto et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2007)
Distinct clinical and pathological features are associated with the BRAF T1799A(V600E) mutation in primary melanoma
Wendy Liu et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2007)
Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma
Liqing Zhuang et al.
MODERN PATHOLOGY (2007)
Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays
Mitchell Stark et al.
CANCER RESEARCH (2007)
Melanoma biology and new targeted therapy
Vanessa Gray-Schopfer et al.
NATURE (2007)
Chemotherapy for metastatic melanoma - Time for a change?
Helen J. Gogas et al.
CANCER (2007)
The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization
Harriet M. Kluger et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2007)
Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations
Juergen Bauer et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2007)
An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells
Keiran S. M. Smalley et al.
CANCER RESEARCH (2007)
Sunitinib: From rational design to clinical efficacy
Laura Q. M. Chow et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
CCI-779 plus cisplatin is highly effective against human melanoma in a SCID mouse xenotranplantation model
C. Thallinger et al.
PHARMACOLOGY (2007)
The inhibitors of apoptosis (IAPs) as cancer targets
Allison M. Hunter et al.
APOPTOSIS (2007)
High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL
Alisa M. Goldstein et al.
CANCER RESEARCH (2006)
Expression of p53-induced apoptosis effector PERP in primary uveal melanomas: Downregulation is associated with aggressive type
Luminita Paraoan et al.
EXPERIMENTAL EYE RESEARCH (2006)
Somatic activation of KIT in distinct subtypes of melanoma
John A. Curtin et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
High frequency of BRAFV600E mutation in acquired nevi and small congenital nevi, but low frequency of mutation in medium-sized congenital nevi
Nami Ichii-Nakato et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2006)
Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies
Gerald Saldanha et al.
CLINICAL CANCER RESEARCH (2006)
The effect of imatinib mesylate (Glivec) on human tumor-derived cells
Louise A. Knight et al.
ANTI-CANCER DRUGS (2006)
CDKN2A common variant and multi-organ cancer risk -: a population-based study
T Dedniak et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Loss of proapoptotic Bcl-2-related multidomain proteins in primary melanomas is associated with poor prognosis
Lothar F. Fecker et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2006)
Extracellular signal-regulated kinase-dependent proliferation is mediated through the protein kinase A/B-Raf pathway in human uveal melanoma cells
A Calipel et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Uveal and conjunctival malignant melanoma in Denmark 1943-97: Observed and relative survival of patients followed through 2002
P Isager et al.
OPHTHALMIC EPIDEMIOLOGY (2006)
Comprehensive analysis of the p53 status in mucosal and cutaneous melanomas
C Gwosdz et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
BRAF mutation predicts sensitivity to MEK inhibition
DB Solit et al.
NATURE (2006)
High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma
MH Abdel-Rahman et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Cutaneous melanoma: available therapy for metastatic disease
Ahmad A. Tarhini et al.
DERMATOLOGIC THERAPY (2006)
MITF: master regulator of melanocyte development and melanoma oncogene
Carmit Levy et al.
TRENDS IN MOLECULAR MEDICINE (2006)
Distinct sets of genetic alterations in melanoma
JA Curtin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Mammalian cyclin-dependent kinases
M Malumbres et al.
TRENDS IN BIOCHEMICAL SCIENCES (2005)
Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin
KR Molhoek et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2005)
Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample
CB Begg et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
A potential role for TGFβ in the regulation of uveal melanoma adhesive interactions with the hepatic endothelium
JKL Woodward et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2005)
The Ras/Raf/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma
F Meier et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2005)
T1799A BRAF mutations in conjunctival melanocytic lesions
N Goldenberg-Cohen et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2005)
Analysis of mutations in B-RAF, N-RAS, and H-RAS genes in the differential diagnosis of Spitz nevus and spitzoid melanoma
MCRF van Dijk et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2005)
BRAFE600-associated senescence-like cell cycle arrest of human naevi
C Michaloglou et al.
NATURE (2005)
Immunohistochemical expression of phospho-Akt in uveal melanoma
VS Saraiva et al.
MELANOMA RESEARCH (2005)
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
LA Garraway et al.
NATURE (2005)
Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS
W Zuidervaart et al.
BRITISH JOURNAL OF CANCER (2005)
Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis
C Willmore-Payne et al.
HUMAN PATHOLOGY (2005)
Prognostic significance of activated Akt expression in melanoma: A clinicopathologic study of 292 cases
DL Dai et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
PUMA expression is significantly reduced in human cutaneous melanomas
AM Karst et al.
ONCOGENE (2005)
Prevalence of Exon 15 BRAF mutations in primary melanoma of the superficial spreading, nodular, acral, and lentigo maligna subtypes
J Lang et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2005)
Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas
J Reifenberger et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Metastatic pattern and survival in disseminated conjunctival melanoma -: Implications for sentinel lymph node biopsy
S Tuomaala et al.
OPHTHALMOLOGY (2004)
Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma
H Tsao et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2004)
Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma
MB Lens et al.
BRITISH JOURNAL OF DERMATOLOGY (2004)
High BRAF mutation frequency does not characterize all melanocytic tumor types
G Saldanha et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Effects of G-protein mutations on skin color
CD Van Raamsdonk et al.
NATURE GENETICS (2004)
Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors
F Facchetti et al.
APOPTOSIS (2004)
Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis
M Chawla-Sarkar et al.
CELL DEATH AND DIFFERENTIATION (2004)
Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: Implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma
KI Amiri et al.
CANCER RESEARCH (2004)
BRAF mutations are detectable in conjunctival but not uveal melanomas
HE Spendlove et al.
MELANOMA RESEARCH (2004)
Rapamycin inhibits doxorubicin-induced NF-κB/Rel nuclear activity and enhances the apoptosis of melanoma cells
MF Romano et al.
EUROPEAN JOURNAL OF CANCER (2004)
BRAF point mutations in primary melanoma show different prevalences by subtype
Y Sasaki et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2004)
Developments in the management of uveal melanoma
B Damato
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2004)
Dissecting karyotypic patterns in malignant melanomas: Temporal clustering of losses and gains in melanoma karyotypic evolution
M Hoglund et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Deregulated Akt3 activity promotes development of malignant melanoma
JM Stahl et al.
CANCER RESEARCH (2004)
Conditional expression of exogenous Bcl-Xs triggers apoptosis in human melanoma cells in vitro and delays growth of melanoma xenografts
AM Hossini et al.
FEBS LETTERS (2003)
Microphthalmia-associated transcription factor (MITF) is required but is not sufficient to induce the expression of melanogenic genes
C Gaggioli et al.
PIGMENT CELL RESEARCH (2003)
Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells
KSM Smalley et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations
M Eskandarpour et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Genetics of melanoma predisposition
NK Hayward
ONCOGENE (2003)
Apoptosis and melanoma chemoresistance
MS Soengas et al.
ONCOGENE (2003)
PTEN signaling pathways in melanoma
H Wu et al.
ONCOGENE (2003)
Expression of the c-kit receptor in choroidal melanomas
F Mouriaux et al.
MELANOMA RESEARCH (2003)
Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction
JC Schmollinger et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Absence of exon 15 BRAF germline mutations in familial melanoma
J Lang et al.
HUMAN MUTATION (2003)
Expression of somatostatin receptors in uveal melanomas
N Ardjomand et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2003)
Expression of c-met tyrosine kinase receptor is biologically and prognostically relevant for primary cutaneous malignant melanomas
J Cruz et al.
ONCOLOGY (2003)
VEGF-Trap: A VEGF blocker with potent antitumor effects
J Holash et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Prognostic value of clinical and histopathological parameters in conjunctival melanomas: a retrospective study
G Anastassiou et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2002)
Rarity of CDK4 germline mutations in familial melanoma
AM Goldstein et al.
MELANOMA RESEARCH (2002)
Loss of p14(ARF) expression in melanoma
R Dobrowolski et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2002)
Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development
G Li et al.
ONCOGENE (2001)
Patterns of regional and distant metastasis in patients with conjunctival melanoma - Experience at a cancer center over four decades
B Esmaeli et al.
OPHTHALMOLOGY (2001)
MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations
NF Box et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2001)
Deregulation of the Rb and p53 pathways in uveal melanoma
MA Brantley et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
TNF-related apoptosis-inducing ligand-induced apoptosis of melanoma is associated with changes in mitochondrial membrane potential and perinuclear clustering of mitochondria
WD Thomas et al.
JOURNAL OF IMMUNOLOGY (2000)
Resistance to CD95/Fas-induced and ceramide-mediated apoptosis of human melanoma cells is caused by a defective mitochondrial cytochrome c release
M Raisova et al.
FEBS LETTERS (2000)
Allelic losses on chromosome arm 10q and mutation of the PTEN (MMAC1) tumour suppressor gene in primary and metastatic malignant melanomas
J Reifenberger et al.
VIRCHOWS ARCHIV-AN INTERNATIONAL JOURNAL OF PATHOLOGY (2000)
Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma
H Tsao et al.
ARCHIVES OF DERMATOLOGY (2000)
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
MR Middleton et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
